* indicates required field
Length: 1
Source of Standard: NAACCR
Section Name: Stage/Prognostic Factors
Year Implemented: 2018
Version Implemented: 18
Record Types: A, M, C, I
XML NAACCR ID: ceaPretreatmentInterpretation
Parent XML Element: Tumor
Required Status:
NPCR Collect: . - No recommendations
CoC Collect: RS - Required, site specific
SEER Collect: RS - Required, site specific
CCCR Collect: RS* - Required, site specific; when available
Description:
CEA (Carcinoembryonic Antigen) Pretreatment Interpretation refers to the interpretation of the CEA value prior to treatment. CEA is a glycoprotein that is produced by adenocarcinomas from all sites as well as many squamous cell carcinomas of the lung and other sites. CEA may be measured in blood, plasma or serum. CEA is a prognostic marker for adenocarcinomas of the appendix, colon and rectum and is used to monitor response to treatment
Rationale:
CEA (Carcinoembryonic Antigen) is a Registry Data Collection Variable for AJCC 8. CEA (Carcinoembryonic Antigen) Pretreatment Interpretation was previously collected as Colon and Rectum, CS SSF #1.
Item Data Type:
digits
Allowable Values
0-3, 7-9
Codes:
0 |
CEA negative/normal; within normal limits |
|---|---|
1 |
CEA positive/elevated |
2 |
Borderline |
3 |
Undetermined if positive or negative (normal values not available) |
7 |
Test ordered, results not in chart |
8 |
Not applicable: Information not collected for this case |
9 |
Not documented in medical record |
Code Notes:
Each Site-Specific Data Item (SSDI) applies only to selected primary sites, histologies, and years of diagnosis. Depending on applicability and standard-setter requirements, SSDIs may be left blank.